Pathogenesis of Chagas Disease: an Emphasis for Transplant Patient Populations
- 7 Downloads
Purpose of Review
Chagas disease is a neglected tropical disease that affects millions of people in the Americas. Reactivation of the infection can occur in the immunosuppressed host, often after organ transplantation. This article aims to review the pathogenesis of Chagas disease with special emphasis on transplant populations in an effort to inform clinicians about the potential risk for reactivation of Chagas disease in high-risk populations.
Reactivation of Chagas disease is most common in the recipient who had Chagas cardiomyopathy and least common in the recipient of non-heart tissues from Chagas patients. T cell suppression associated with AIDS and transplantation is a major risk factor for reactivation. Certain drugs are associated with a higher risk for reactivation post-transplant, such as mycophenolate motefil. TNF-α inhibitors may also be associated with reactivation of Chagas disease. Routine PCR after transplantation seems to be an adequate tool for early diagnosis after transplant.
Transplant physicians should be aware of Chagas disease as a potential transmission risk for donors originating from endemic areas. The highest transmission risk being in cardiac donors and lesser risk for liver and kidney donors. Standardized monitoring protocols seem to detect the infection early, reducing the risk for complications from reactivation of Chagas disease in this population.
KeywordsChagas disease Transplant population Reactivation of Chagas Trypanosoma cruzi Pathogenesis
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Chagas Disease (American trypanosomiasis): Epidemiology. World Health Organization. 2018. http://www.who.int/chagas/epidemiology/en/. Accessed 1 Oct 2018.
- 4.• Requena-Méndez A, Aldasoro E, de Lazzari E, Sicuri E, Brown M, Moore DA, et al. Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2015;9:e0003540. https://doi.org/10.1371/journal.pntd.0003540 Nice baseline epidemiological study of the prevalence of Chagas in Europe to estimate the burden of disease at a continent level. CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Cucunubá ZM, Okuwoga O, Basáñez MG, Nouvellet P. Increased mortality attributed to Chagas disease: a systematic review and meta-analysis. Parasit Vectors. 2016;27:9–42.Google Scholar
- 21.•• Acevedo GR, Girard MC, Gómez KA. The unsolved jigsaw puzzle of the immune response in Chagas disease. Front Immunol. 2018;9:1929. https://doi.org/10.3389/fimmu.2018.01929 One of the best extensive detailed review on the immunopathogenesis of T. cruzi infection to date. CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Dóka G, Radik M, Krenek P, Kyselovic J, Klimas J. Microrna-208a and its host gene cardiac myosin heavy chain Myh6 are involved in hypertrophic heart dysfunction. J Hypertens. 2015;33:e1. https://doi.org/10.1097/01.hjh.0000467352.59037.c9.CrossRefGoogle Scholar
- 28.•• Pérez-Antón E, Egui A, Thomas MC, Puerta CJ, González JM, Cuéllar A, et al. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients. PLoS Negl Trop Dis. 2018;12:e0006480. https://doi.org/10.1371/journal.pntd.0006480 This study provides evidence that benznidazole impact the function of the T cells in patients with chronic Chagas disease suggesting that the treatment effect may immunoregulate the response against T. cruzi infection. CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Reis PG, Ayo CM, de Mattos LC, Brandão de Mattos CC, Sakita KM, de Moraes AG, et al. Genetic polymorphisms of IL17 and Chagas disease in the south and southeast of Brazil. J Immunol Res. 2017. https://doi.org/10.1155/2017/1017621.
- 56.•• Gray EB, La Hoz RM, Green JS, Vikram HR, Benedict T, Rivera H, et al. Reactivation of Chagas disease among heart transplant recipients in the United States, 2012–2016. Transpl Infect Dis. 2018;20:e12996. https://doi.org/10.1111/tid.12996 This study uses an effective approach to diagnose Chagas reactivation after transplant before symptoms developed. CrossRefPubMedGoogle Scholar
- 58.• Herwaldt BL, Dougherty CP, Allen CK, et al. Characteristics of patients for whom benznidazole was released through the CDC-sponsored investigational new drug Program for treatment of Chagas disease—United States, 2011–2018. MMWR Morb Mortal Wkly Rep. 2018. https://doi.org/10.15585/mmwr.mm6729a3 Review of benznidazole treatment in the US by CDC prior FDA-approval of the drug. Clinicians should be aware of the commercially availability of this drug in the US.
- 59.de Freitas VL, da Silva SC, Sartori AM, Bezerra RC, Westphalen EV, Molina TD, et al. Real-time PCR in HIV/Trypanosoma cruzi coinfection with and without Chagas disease reactivation: association with HIV viral load and CD4 level. PLoS Negl Trop Dis. 2011;5:e1277. https://doi.org/10.1371/journal.pntd.0001277.CrossRefPubMedPubMedCentralGoogle Scholar
- 60.Balderramo D, Bonisconti F, Alcaraz A, Giordano E, Sánchez A, Barrabino M, et al. Chagas disease and liver transplantation: experience in Argentina using real-time quantitative PCR for early detection and treatment. Transpl Infect Dis. 2017;19. https://doi.org/10.1111/tid.12782.
- 61.• Benvenuti LA, Roggério A, Cavalcanti MM, Nishiya AS, Levi JE. An autopsy-based study of Trypanosoma cruzi persistence in organs of chronic chagasic patients and its relevance for transplantation. Transpl Infect Dis. 2017:19. doi: https://doi.org/10.1111/tid.12783. This study shows that solid organs (aside from the heart) of T. cruzi -infected donors can be used for transplantation. However, a close monitoring for reactivation should be followed by the clinician.
- 63.Cardillo F, de Pinho RT, Antas PR, Mengel J. Immunity and immune modulation in Trypanosoma cruzi infection. Pathog Dis. 2015;73. https://doi.org/10.1093/femspd/ftv082.
- 65.Pereira IR, Vilar-Pereira G, Marques V, da Silva AA, Caetano B, Moreira OC, et al. A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. PLoS Pathog. 2015;11:e1004594. https://doi.org/10.1371/journal.ppat.1004594.CrossRefPubMedPubMedCentralGoogle Scholar